Genetics Co. Hid Cancer Test Overbilling, Investor Says
Myriad Genetics Inc. and its executives hid from shareholders that it was overbilling Medicare and Medicaid for a hereditary cancer test in a scheme that eventually drew the U.S. Department of...To view the full article, register now.
Already a subscriber? Click here to view full article